General Announcement::Glenmark receives ANDA approval for Tacrolimus Ointment, 0.1 per.

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
18-Apr-2018 11:37:58
Status
New
Announcement Sub Title
Glenmark receives ANDA approval for Tacrolimus Ointment, 0.1 per.
Announcement Reference
SG180418OTHR7LQ7
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
18/04/2018 09:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark receives ANDA approval for Tacrolimus Ointment, 0.1 per.

Attachments

PR_18042018.pdf
Total size =391K